FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/03/2026
Voltar para busca
Dado oficial do USPTO
DERMATOPLEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 10, 42, 44
Data de depósito
31/07/2023
Data de registro
19/08/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/08/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
AU
Examinador
VENGURLEKAR, SAGAR S
Unidade examinadora
M80
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "DERMATOPLEX".
Titulares e representantes
Titulares
SpeeDx Pty Ltd
Representantes
Jefferson F. Scher Carr & Ferrell LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical reagents for non-medical purposes; chemical reagents for scientific purposes; chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with amplificationanalysis or labeling of nucleic acid; enzyme preparations for industrial purposes to identify pathogensinfectionsinfectious diseases; enzymes for scientific and research purposes; nucleic acids for scientific purposes; nucleic recombinant acids for scientific purposes; acidsnucleic recombinant acids to identify pathogensinfectionsinfectious diseases for scientific purposes; polymerase for scientific purposes; none of the foregoing for use in promoting plant growth or in enhancing the effectiveness of plant nutrients
Classe 5
Reagents for medical and veterinary use; nucleic acid amplification reagents for medical use; nucleic acid sequencing programs for medical use to identify pathogensinfectionsinfectious diseases; chemical preparations containing enzymes for medical purposes for treating infections and infectious diseases; chemical preparations containing enzymes for treating infections and infectious diseases for pharmaceuticalveterinary and medical purposes; enzyme preparations for pharmaceuticalveterinary and medical purposes; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detectionto diagnose and identify pathogensinfectionsinfectious diseases; diagnostic kits comprising diagnostic agentspreparations and substances for medical and veterinary use; diagnostic kits comprised of medical diagnostic reagents and assays for medical laboratory use in analysis of gene expressionprotein expressionmetabolite expressioninflammationimmune-suppressionimmune disordersall for testing of bodily fluids for use in disease detectionto diagnose and identify pathogensinfectionsinfectious diseases; none of the foregoing for use in or as a medicated shampoo
Classe 10
Surgicalmedical and veterinary apparatus and instruments for diagnosis of diseasefor detection and identification of pathogensfor the detection of antibiotic resistancefor the analysis of gene expressionprotein expressionmetabolic expressioninflammationimmune-suppression and immune disorders for genotypinganalysis of polymorphismsdetection of acquired or inherited genetic mutationsdetection and analysis of epigenetic alterationsanalysis of response to therapy for treatment of infectious diseasesimmunological diseases and autoimmune diseases; diagnostic testing apparatus and instruments for medical purposesfor diagnosis of diseasefor detection and identification of pathogensfor the detection of antibiotic resistancefor the analysis of gene expressionprotein expressionmetabolic expressioninflammationimmune-suppression and immune disorders for genotypinganalysis of polymorphismsdetection of acquired or inherited genetic mutationsdetection and analysis of epigenetic alterationsanalysis of response to therapy for treatment of infectious diseasesimmunological diseases and autoimmune diseases; medical diagnostic apparatus for testing for diagnosis of diseasefor detection and identification of pathogensfor the detection of antibiotic resistancefor the analysis of gene expressionprotein expressionmetabolic expressioninflammationimmune-suppression and immune disorders for genotypinganalysis of polymorphismsdetection of acquired or inherited genetic mutationsdetection and analysis of epigenetic alterationsanalysis of response to therapy for treatment of infectious diseasesimmunological diseases and autoimmune diseases; point of care medical devicesa device for testing for diagnosis of diseasefor detection and identification of pathogensfor the detection of antibiotic resistancefor the analysis of gene expressionprotein expressionmetabolic expressioninflammationimmune-suppression and immune disorders for genotypinganalysis of polymorphismsdetection of acquired or inherited genetic mutationsdetection and analysis of epigenetic alterationsanalysis of response to therapy for treatment of infectious diseasesimmunological diseases and autoimmune diseases; diagnostic kits consisting primarily of probesbuffers and reagents for use in microbial testing; Anatomic pathology specimen collection kit comprising glass slidescentrifuge tubesformalin jarscoplin jarsinsert to hold slides and jarsabsorbent clothprinted instructionsall for medical use
Classe 42
Scientific research in the field of genetics; scientific research in the field of genetics and genetic engineering; research and development services in the field of chemistry; scientific research in the field of chemistry; research in the field of chemistry; research laboratory analysis services in the field of chemistry; development services in the field of medical diagnostic apparatuses; design of medical diagnostic apparatuses; research in the field of molecular sciences; data analysis for scientific research purposes in the field of scientific and medical experiments and tests; biologicalbacteriologicalchemicalbiochemicalDNARNAproteinpolynucleic acid and molecular analysis and evaluation servicesfor scientific research purposes; DNA and RNA and polynucleic acid and protein sequencinganalysis and evaluation services for scientific research purposes; genome sequencing services and the analysis and evaluation of data resulting therefrom for scientific research purposes; providing reports relating to scientific and medical experimentsthe results of scientific and medical experiments and teststhe analysis and evaluation of scientific and medical datadata generated by scientific and medical experiments and tests; scientific and medical research and development servicesfor scientific research purposes; custom design and development of biochemical assays
Classe 44
Medical services; human healthcare services in the field of diagnosis and identification of pathogens infections and infectious diseases; medical testing services relating to the diagnosis and treatment of disease; genetic testing for medical purposes; medical and health services in the field of DNA and genetic testing; medical diagnostic services in the nature of medical testing and analysis; molecular diagnostics testing for medical purposes; providing medical information in the field of genetic and treatment information for diseases and disorders for diagnostic and treatment purposes; analysis of medical diagnostic images and medical molecular tests for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/02/2026
FIMP
FINAL DISPOSITION PROCESSED
26/02/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/11/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/08/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
19/08/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/06/2025
PUBO
PUBLISHED FOR OPPOSITION
03/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/05/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/05/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/03/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/02/2025
GNFR
FINAL REFUSAL E-MAILED
11/02/2025
CNFR
FINAL REFUSAL WRITTEN
11/02/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/02/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/02/2025
DOCK
ASSIGNED TO EXAMINER
13/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/10/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/10/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/10/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
22/10/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
22/10/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
22/10/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
22/10/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
22/10/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
22/10/2024
ATRV
ATTORNEY REVIEW COMPLETED
12/08/2024
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
07/07/2024
RFNT
REFUSAL PROCESSED BY IB
13/05/2024
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
12/05/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
24/04/2024
RFRR
REFUSAL PROCESSED BY MPU
23/04/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/04/2024
CNRT
NON-FINAL ACTION WRITTEN
03/04/2024
DOCK
ASSIGNED TO EXAMINER
01/04/2024
MAFR
APPLICATION FILING RECEIPT MAILED
12/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/09/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/09/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace DERMATOPLEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.